＜＜Back

Next＞＞

Vol. 39　No. 3　2011

Pharmacokinetic and pharmacodynamic characteristics of C.E.R.A., a novel continuous erythropoietin receptor activator
─Results of pre-clinical studies─

M. Tamura, et al.

Jpn Pharmacol Ther 2011　39(3) 249-58

---

Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative

M. Abe, et al.

Jpn Pharmacol Ther 2011　39(3) 261-74

Effects of eldecalcitol on the pharmacokinetics of the CYP3A4 substrate, simvastatin
─Double blind, randomized, placebo-controlled, parallel group

K. Miyata, et al.

Jpn Pharmacol Ther 2011　39(3) 275-85

---

Open-label, multicentre, single dose study of eldecalcitol pharmacokinetics in patients with impaired liver function

Y. Ikeda, et al.

Jpn Pharmacol Ther 2011　39(3) 287-97

---

Pharmacokinetics of eldecalcitol in primary osteoporosis patients
─Randomized, double-blind, multicentre, long-term phase III clinical study─

K. Miyata, et al.

Jpn Pharmacol Ther 2011　39(3) 299-307

---

Reproductive and developmental toxicity studies of monoammonium glycyrrhizinate by intravenous administration in rats and rabbits

T. Yoshida, et al.

Jpn Pharmacol Ther 2011　39(3) 309-27

---

Evaluation of the safety of generic thromboxane synthetase inhibitors

Y. Ikeda, et al.

Jpn Pharmacol Ther 2011　39(3) 329-32

---

An impact of ezetimibe on the carotid arterial wall elasticity in patients with hyper-LDL-cholesterolemia

T. Yamagishi, et al.

Jpn Pharmacol Ther 2011　39(3) 333-40

---

Evaluation of safety of excessive intake of β-glucan enriched barley flour product

K. Tsubaki, et al.

Jpn Pharmacol Ther 2011　39(3) 341-7